{"id":8223,"date":"2024-11-20T10:00:16","date_gmt":"2024-11-20T02:00:16","guid":{"rendered":"https:\/\/www.eisai.com.cn\/?p=8223"},"modified":"2024-11-22T13:59:58","modified_gmt":"2024-11-22T05:59:58","slug":"%e6%8a%97%e7%99%8c%e8%8d%af%e7%89%a9tasfygo%e7%89%87%e5%89%8235mg%ef%bc%88-tasurgratinib-succinate%ef%bc%89%e5%9c%a8%e6%97%a5%e6%9c%ac%e4%b8%8a%e5%b8%82-%e7%94%a8%e4%ba%8e","status":"publish","type":"post","link":"https:\/\/www.eisai.com.cn\/2024\/11\/20\/%e6%8a%97%e7%99%8c%e8%8d%af%e7%89%a9tasfygo%e7%89%87%e5%89%8235mg%ef%bc%88-tasurgratinib-succinate%ef%bc%89%e5%9c%a8%e6%97%a5%e6%9c%ac%e4%b8%8a%e5%b8%82-%e7%94%a8%e4%ba%8e\/","title":{"rendered":"\u6297\u764c\u836f\u7269\u201cTASFYGO\u00ae\u7247\u524235mg\u201d\uff08 TASURGRATINIB SUCCINATE\uff09\u5728\u65e5\u672c\u4e0a\u5e02 \u7528\u4e8e\u6cbb\u7597\u643a\u5e26FGFR2\u57fa\u56e0\u878d\u5408\u6216\u91cd\u6392\u7684\u80c6\u9053\u764c"},"content":{"rendered":"
\n
\u536b\u6750\u5ba3\u5e03\uff0c\u5df2\u5728\u65e5\u672c\u4e0a\u5e02\u6210\u7ea4\u7ef4\u7ec6\u80de\u751f\u957f\u56e0\u5b50\u53d7\u4f53\uff08FGFR\uff09\u9009\u62e9\u6027\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\u201cTASFYGO\u00ae\u7247\u524235mg\u201d<\/strong>\uff08\u901a\u7528\u540d\uff1atasurgratinib succinate\uff09\uff0c\u7528\u4e8e\u6cbb\u7597\u5316\u7597\u540e\u75c5\u60c5\u8fdb\u5c55\u7684\u3001\u643a\u5e26FGFR2\u57fa\u56e0\u878d\u5408\u6216\u91cd\u6392\u7684\u4e0d\u53ef\u5207\u9664\u80c6\u9053\u764c\u60a3\u8005\u3002\u8be5\u4ea7\u54c1\u4e8e2024\u5e749\u670824\u65e5\u83b7\u5f97\u65e5\u672c\u7684\u751f\u4ea7\u548c\u9500\u552e\u8bb8\u53ef\uff0c\u5e76\u4e8e11\u670820\u65e5\u88ab\u5217\u5165\u65e5\u672c\u56fd\u5bb6\u533b\u7597\u4fdd\u9669\u836f\u54c1\u4ef7\u683c\u540d\u5f55\u3002<\/section>\n
\n

\"\"<\/p>\n<\/section>\n

\n

TASFYGO\uff0c\u7531\u536b\u6750\uff08Eisai\uff09\u7b51\u6ce2\u7814\u7a76\u5b9e\u9a8c\u5ba4\u81ea\u4e3b\u7814\u53d1\uff0c\u662f\u4e00\u79cd\u53ef\u53e3\u670d\u7684\u65b0\u578b\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff0c\u5bf9FGFR1\u3001FGFR2\u548cFGFR3\u8868\u73b0\u51fa\u9009\u62e9\u6027\u6291\u5236\u6d3b\u6027\u3002TASFYGO\u5728\u65e5\u672c\u83b7\u6279\u662f\u57fa\u4e8e\u591a\u9879\u6570\u636e\uff0c\u5305\u62ec\u536b\u6750\u5728\u65e5\u672c\u548c\u4e2d\u56fd\u5f00\u5c55\u7684\u4e00\u9879\u591a\u4e2d\u5fc3\u3001\u5f00\u653e\u6027\u3001\u5355\u81c2\u4e34\u5e8aII\u671f\u8bd5\u9a8c\uff08\u7814\u7a76201\uff09\u7684\u7ed3\u679c1<\/sup>\u30022024\u5e748\u6708\uff0cNihon Stery, Inc.\uff08\u603b\u90e8\uff1a\u4e1c\u4eac\uff09\u7814\u53d1\u7684\u914d\u5957\u8bca\u65ad\u8bd5\u5242\u76d2\u201cAmoyDx\u00ae FGFR2 Break-apart FISH Probe Kit\u201d\u4e5f\u83b7\u6279\u4e0a\u5e02\uff0c\u8be5\u8bd5\u5242\u76d2\u7528\u4e8e\u68c0\u6d4b\u80c6\u9053\u764c\u60a3\u8005\u7684FGFR2\u57fa\u56e0\u878d\u5408\u6216\u91cd\u6392\uff0c\u4ee5\u786e\u5b9a\u662f\u5426\u9002\u5408\u4f7f\u7528TASFYGO\u8fdb\u884c\u6cbb\u75972<\/sup>\u3002<\/p>\n

\u636e\u4f30\u8ba1\uff0c\u65e5\u672c\u80c6\u9053\u764c\u60a3\u8005\u4eba\u6570\u7ea6\u4e3a 22,000 \u4eba3,4<\/sup>\uff0c\u4e94\u5e74\u76f8\u5bf9\u751f\u5b58\u7387\u7ea6\u4e3a 25%3<\/sup>\uff0c\u662f\u7ee7\u80f0\u817a\u764c\u4e4b\u540e\u9884\u540e\u7b2c\u4e8c\u5dee\u7684\u96be\u6cbb\u6027\u764c\u75c7\u3002\u4e0e\u5176\u4ed6\u764c\u75c7\u76f8\u6bd4\uff0c\u80c6\u7ba1\u764c\u7684\u836f\u7269\u6cbb\u7597\u65b9\u6848\u5341\u5206\u6709\u9650\uff0c\u56e0\u6b64\u5b58\u5728\u5927\u91cf\u672a\u6ee1\u8db3\u7684\u533b\u7597\u9700\u6c42\u3002\u80c6\u9053\u764c\u4e2d\u670915-30%\u4e3a\u809d\u5185\u80c6\u7ba1\u764c\uff0c\u5176\u4e2d\u53c8\u6709\u7ea65-14% \u5b58\u5728 FGFR2 \u57fa\u56e0\u878d\u5408\u6216\u91cd\u63925,6,7<\/sup>\u3002FGFR\u9057\u4f20\u53d8\u5f02\uff08\u5982\uff1a\u57fa\u56e0\u878d\u5408\uff09\u88ab\u8ba4\u4e3a\u4e0e\u764c\u7ec6\u80de\u7684\u589e\u6b96\u3001\u5b58\u6d3b\u548c\u8fc1\u79fb\u4ee5\u53ca\u80bf\u7624\u8840\u7ba1\u751f\u6210\u548c\u8010\u836f\u6027\u5bc6\u5207\u76f8\u5173\u3002\u9274\u4e8e\u5728\u5176\u4ed6\u5404\u79cd\u764c\u75c7\u548c\u80c6\u9053\u764c\u4e2d\u90fd\u89c2\u5bdf\u5230\u4e86FGFR\u9057\u4f20\u53d8\u5f02\uff0cFGFR\u4f5c\u4e3a\u764c\u75c7\u6cbb\u7597\u7684\u6f5c\u5728\u9776\u70b9\u6b63\u65e5\u76ca\u53d7\u5230\u5173\u6ce8\u3002<\/p>\n

TASFYGO \u5728\u5ddd\u5c9b\u5de5\u4e1a\u56ed\uff08\u5c90\u961c\u53bf\uff09\u751f\u4ea7\uff0c\u91c7\u7528\u521b\u65b0\u7684\u8fde\u7eed\u751f\u4ea7\u548c\u5b9e\u65f6\u653e\u884c\u68c0\u6d4b\u6280\u672f\uff0c\u8fd9\u79cd\u751f\u4ea7\u6280\u672f\u53ef\u786e\u4fdd\u751f\u4ea7\u8fc7\u7a0b\u4e2d\u7684\u4ea7\u54c1\u8d28\u91cf\u3002\u8fde\u7eed\u751f\u4ea7\u662f\u4e00\u79cd\u751f\u4ea7\u65b9\u6cd5\uff0c\u4ece\u539f\u6750\u6599\u8f93\u5165\u5230\u5236\u5242\u5f62\u6210\u7684\u6574\u4e2a\u8fc7\u7a0b\u90fd\u662f\u8fde\u7eed\u8fdb\u884c\u7684\u3002\u901a\u8fc7\u91c7\u7528\u5b9e\u65f6\u8d28\u91cf\u76d1\u63a7\u6280\u672f\uff0c\u5c06\u591a\u4e2a\u751f\u4ea7\u6d41\u7a0b\u6574\u5408\u5728\u4e00\u8d77\uff0c\u5b9e\u73b0\u81ea\u52a8\u751f\u4ea7\u3002\u4e0e\u4e13\u6ce8\u4e8e\u4ea7\u54c1\u653e\u884c\u68c0\u6d4b\u7684\u4f20\u7edf\u5de5\u827a\u76f8\u6bd4\uff0c\u8fd9\u79cd\u65b9\u6cd5\u53ef\u4ee5\u5229\u7528\u751f\u4ea7\u8fc7\u7a0b\u4e2d\u7684\u6570\u636e\uff0c\u901a\u8fc7\u81ea\u52a8\u5316\u51cf\u5c11\u4eba\u4e3a\u9519\u8bef\uff0c\u4ece\u800c\u5b9e\u73b0\u66f4\u9ad8\u7684\u8d28\u91cf\u63a7\u5236\u3002<\/p>\n

\u536b\u6750\u81f4\u529b\u4e8e\u901a\u8fc7\u4e3a\u643a\u5e26FGFR2\u57fa\u56e0\u878d\u5408\u6216\u91cd\u6392\u7684\u80c6\u9053\u764c\u60a3\u8005\u63d0\u4f9bTASFYGO\u8fd9\u4e00\u5168\u65b0\u6cbb\u7597\u9009\u62e9\uff0c\u4e0d\u65ad\u52aa\u529b\u6ee1\u8db3\u764c\u75c7\u60a3\u8005\u5176\u5bb6\u5c5e\u4ee5\u53ca\u533b\u7597\u4e13\u4e1a\u4eba\u58eb\u7684\u591a\u6837\u5316\u9700\u6c42\uff0c\u5e76\u4e3a\u4ed6\u4eec\u5e26\u6765\u66f4\u591a\u798f\u7949\u3002<\/p>\n<\/section>\n

\n
\n<\/section>\n
\n

1. Furuse J. et al. Pivotal single-arm, phase 2 trial of tasurgratinib for patients with fibroblast growth factor receptor (FGFR)-2 gene fusion-positive cholangiocarcinoma (CCA). 2024 ASCO Gastrointestinal Cancers Symposium;<\/em><\/p>\n

Abstract No. 471. https:\/\/ascopubs.org\/doi\/pdf\/10.1200\/JCO.2024.42.3_suppl.471<\/em><\/p>\n

2. AmoyDx\u00ae FGFR2 Break-apart FISH Probe Kit Approved as Companion Diagnostic for Eisai\u2019s Tasurgratinib in Japan.<\/em><\/p>\n

Available at: https:\/\/www.amoydiagnostics.com\/about\/press-releases\/245 Last accessed: September 2024.<\/em><\/p>\n

3. Latest statistics, Cancer Information Service, National Cancer Center, Japan. (Japanese only)<\/em><\/p>\n

4. The 23rd Follow-up Survey Reports for Primary Liver Cancer Cases in Japan (2014-2015), 2023. (Japanese only)<\/em><\/p>\n

5. Arai Y. et al., Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma, Hepatology, 2014, 59, 1427-1434.<\/em><\/p>\n

6. Maruki Y. et al., Molecular detection and clinicopathological characteristics of advanced\/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study), J Gastroenterol. 2021; 56(3), 250-260.<\/em><\/p>\n

7. Tsujie M. et al., Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic<\/em><\/p>\n

cholangiocarcinoma, Jpn J Clin Oncol. 2021; 51(6): 911-917.<\/em><\/p>\n<\/section>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

\u536b\u6750\u5ba3\u5e03\uff0c\u5df2\u5728\u65e5\u672c\u4e0a\u5e02\u6210\u7ea4\u7ef4\u7ec6\u80de\u751f\u957f\u56e0\u5b50\u53d7\u4f53\uff08FGFR\uff09\u9009\u62e9\u6027\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\u201cTASFYGO\u00ae\u7247\u524235mg\u201d\uff08\u901a\u7528\u540d\uff1atasurgratinib succinate\uff09\uff0c\u7528\u4e8e\u6cbb\u7597\u5316\u7597\u540e\u75c5\u60c5\u8fdb\u5c55\u7684\u3001\u643a\u5e26FGFR2\u57fa\u56e0\u878d\u5408\u6216\u91cd\u6392\u7684\u4e0d\u53ef\u5207\u9664\u80c6\u9053\u764c\u60a3\u8005\u3002\u8be5\u4ea7\u54c1\u4e8e2024\u5e749\u670824\u65e5\u83b7\u5f97\u65e5\u672c\u7684\u751f\u4ea7\u548c\u9500\u552e\u8bb8\u53ef\uff0c\u5e76\u4e8e11\u670820\u65e5\u88ab\u5217\u5165\u65e5\u672c\u56fd\u5bb6\u533b\u7597\u4fdd\u9669\u836f\u54c1\u4ef7\u683c\u540d\u5f55\u3002<\/p>\n","protected":false},"author":1,"featured_media":8226,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[],"class_list":["post-8223","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-zh"],"_links":{"self":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/8223"}],"collection":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/comments?post=8223"}],"version-history":[{"count":3,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/8223\/revisions"}],"predecessor-version":[{"id":8229,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/8223\/revisions\/8229"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/media\/8226"}],"wp:attachment":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/media?parent=8223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/categories?post=8223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/tags?post=8223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}